Novo Nordisk announced that Wegovy (semaglutide) injection 0.25 mg and 0.5 mg and Ozempic are now available at a limited time price of $199 per month to new self-pay patients between now and March 31, 2026.
This introductory offer is good for the first two months of therapy and applies to the two lowest doses (0.25 mg and 0.5 mg) of Wegovy or Ozempic. After those two months, patients will move to the new standard monthly self-pay price which Novo Nordisk is lowering from $499 to $349 per month. The self-pay cost of Ozempic 2 mg will remain $499 per month.
These offers follow the recent agreement with the US Administration to expand access to medicines for patients living with obesity and other chronic conditions like diabetes, while lowering prices in the direct-to-patient, self-pay channel in 2026. Novo Nordisk is bringing these prices to consumers months in advance of that commitment.
These new offers are part of Novo Nordisk’s ongoing commitment to expand access to authentic, FDA approved semaglutide medicines, Wegovy and Ozempic. They intend to help more people living with chronic diseases afford the treatments they need as well as eliminate the lure of risky, potentially unsafe, compounded “semaglutide” knockoffs.
For patients with commercial insurance coverage who qualify, Novo Nordisk continues to offer savings programs that allow them to pay as little as $0 per month for Wegovy or $25 per month for Ozempic.
“As pioneers of the GLP-1 class, we are committed to ensuring that real, FDA-approved Wegovy® and Ozempic® are affordable and accessible to those who need them,” said Dave Moore, Executive Vice President, US Operations of Novo Nordisk Inc. “The US healthcare system is complex, with different types of insurance and various ways for patients to obtain their medicines. Our new savings offers provide immediate impact, bringing forward greater cost savings for those who are currently without coverage or choose to self-pay. It is part of a larger strategy to expand access that includes building relationships with telehealth providers and major retailers, expanding coverage, and working with the Administration to lower costs for people living with chronic diseases like obesity and type 2 diabetes.”
These self-pay offers can be accessed in multiple ways:
- Directly through wegovy.com or ozempic.com, where patients can register for savings to be used, with a prescription, at over 70,000 pharmacy locations across the US
- NovoCare® Pharmacy, where prescriptions are sent straight from a healthcare provider and patients receive convenient home delivery or the option to pick up prescriptions at one of over 9,000 CVS retail locations
- Other participating organizations and select telehealth providers that work directly with Novo Nordisk, such as Costco, GoodRx, WeightWatchers, Ro, LifeMD, and eMed
Semaglutide is the active ingredient in Wegovy® and Ozempic® and, unlike any other molecule in the GLP-1 class, has FDA-approved medicines with indications for patients with obesity (Wegovy®), type 2 diabetes (Ozempic®), chronic kidney disease (Ozempic®), and cardiovascular disease (Wegovy® and Ozempic®). Millions of people in the US have used semaglutide medicines to help address these chronic conditions, yet there are still patients without adequate coverage seeking improved access.
For more details about these new offers, additional information on supports access and affordability of medicines, or to check cost and coverage, visit Novo Nordisk online.
 injection and Ozempic are now available at limited time price to new self-pay patients.){kind=link}